|
A customer reported receiving erroneous glucose results from an abbott diabetes care device.The customer received adc meter results of "[90mg/dl]" compared to glucose values of "[51mg/dl]" respectively obtained on the comparison device, when plotted on a parkes error grid, fall into the "[c]" zone, showing the difference in values to be clinically significant.There was no report of death, serious injury, or mistreatment associated with this event.
|
|
At this time, product has not yet been returned.An investigation has been performed for the reported complaint information.The device history records (dhrs) for the product were reviewed and the dhrs showed the product passed all tests prior to release.Retain testing was performed for the test strips and all units performed within specification.It is not possible to determine the probable cause of this event.There are mitigations in place to reduce and prevent issues such as disconnected, faulty or damaged components or misuse of the device.All vital manufacturing steps are validated, monitored, and verified during manufacturing to ensure the system is in conformance with the verified design.Labeling is provided to instruct the user on the intended use of all vital parts of the system to minimize misuse.All complaints and complaint trends are investigated to determine if there is a product defect/ deficiency.If a product defect/ deficiency is identified, a risk evaluation is completed and compared to the risk management report, to ensure the risk profile has not changed.Additionally, as a part of abbott¿s post-market surveillance process, all risk evaluations with associated complaint data are reviewed annually to determine if the risk profiles have changed as compared to the product risk management reports.These monitoring processes ensure that all product risk profiles remain acceptable and have a positive benefit/ risk ratio.If the product is returned, a physical investigation will be performed and a follow-up report submitted.This complaint was reviewed and is being submitted as it has been reassessed as reportable as the result of retrospective review associated with a capa.All pertinent information available to abbott diabetes care has been submitted.
|